Stock Ratings / Health Care / BHVN / forecast

NAMS (38) ZLAB (26) SUPN (56) PGEN (35) ⌘ Pro Terminal →

Biohaven Ltd. (BHVN) 12-Month Stock Forecast & Price Target Cone

$16.49 +6.25% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $16.64

Biohaven Ltd. (BHVN) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $2.49B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $16.65 (+0.94%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BHVN)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (46/100 Composite)

🔍 WHY BHVN SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (33% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (26% of score)

FRED Regime × Technicals: 84% of 52W Range • RSI-14 at 61.1 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$12.08-10.8% Next Q

Q2 (-2Q)

Grade D$10.78+28.8% Next Q

Q3 (-1Q)

Grade D$13.88+18.8% Next Q

Current

Grade D$16.49-6.1% Hist 90D α

Trajectory: E (38) → D (46)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BHVN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BHVN currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.62) and Max Pain ($17.31) forces dealer call-delta covering toward $19.15.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BHVN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BHVN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 46%NO 54%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your BHVN Position Size: $10,000

Shares at $16.49: 606.4 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $12.17

$7,380

$-2,620 (-26.2%)

12M Consensus BaseTarget $15.60

$9,460

$-540 (-5.4%)

12M Bull Case BreakoutTarget $19.15

$11,613

+$1,613 (+16.1%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$16	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$18	69%	B
JP MorganUS Large-Cap Research	SELL	$14	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BHVN)

✓Walkthrough of BHVN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BHVN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +71.95%📐 HORIZONTAL RANGE

2026-10-30O $15.46H $16.49L $15.12C $16.49VOL 3.16M

RES: $19.54SUP: $10.24SMA50: $13.62SMA200: $12.23

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BHVN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BHVN Butterfly Map → + Track BHVN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BHVN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BHVN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BHVN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BHVN)

Health Care Rank #437 of 1016 ⚔️ NAMS vs BHVN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BHVN vs. NAMS, ZLAB, SUPN, PGEN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Biohaven Ltd. (BHVN) ranks #437 by composite RQD confidence (46/100, grade D) and #221 by equity capitalization ($2.49B). Within this direct 5-issuer industry benchmark cohort, BHVN leads on earnings valuation at N/A trailing P/E, while SUPN leads on capital efficiency and profitability with -4.5% ROIC and 89.6% gross margin. SUPN currently holds the highest overall quantitative score in the immediate peer group at 56/100 (D+) compared with BHVN at 46/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BHVN ACTIVE Biohaven Ltd.	D	46/100	—	—	-35.0%	+6.25%	$2.49B	Benchmark Subject
NAMS NewAmsterdam Pharma Company N.V.	D-	38/100	—	—	-35.0%	-1.47%	$2.48B	/nams-vs-bhvn →
ZLAB Zai Lab Limited	E	26/100	—	58.3%	-35.0%	-2.95%	$2.51B	/zlab-vs-bhvn →
SUPN Supernus Pharmaceuticals Inc.	D+	56/100	—	89.6%	-4.5%	+1.85%	$2.43B	/supn-vs-bhvn →
PGEN Precigen Inc.	D-	35/100	—	—	-35.0%	+9.21%	$2.38B	/pgen-vs-bhvn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001935979

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Biohaven Ltd. (BHVN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$738.8M, operating cash flow of -$609.4M, and free cash flow of -$610.2M (-4.0% YoY). On the balance sheet, BHVN closed FY2025 with $451.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$738.8M	-$609.4M	-$610.2M	$451.4M	—
FY2024 (FY)	2024-12-31	$0	-$846.4M	-$582.5M	-$586.5M	$615.1M	—
FY2023 (FY)	2023-12-31	$0	-$408.2M	-$331.7M	-$331.7M	—	—

3. BHVN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BHVN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Biohaven Ltd. (NYSE: BHVN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $16.49 (+6.25% 1D, market cap $2.49B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BHVN ranks #437 in composite RQD confidence.

How does BHVN compare to NAMS and ZLAB in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BHVN carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NAMS (NewAmsterdam Pharma Company N.V.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $2.48B) and ZLAB (Zai Lab Limited) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $2.51B). Among the 5-stock peer group, BHVN leads on earnings multiple (N/A) while SUPN leads on capital efficiency (-4.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BHVN?

Per BHVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001935979), Biohaven Ltd. generated $0 in revenue, -$738.8M in net income, and -$610.2M in free cash flow against $451.4M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BHVN trading relative to its 50-day, 200-day, and 52-week technical levels?

BHVN last traded at $16.49 (+6.25% on volume of 2,450,920 shares), positioning the stock +21.07% above its 50-day simple moving average ($13.62) and +34.83% above its 200-day simple moving average ($12.23). Across its 52-week range of $7.48 to $18.24, BHVN sits at the 83.7% percentile with a 14-day RSI of 61.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($14.43 to $18.55).

BHVN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is BHVN's 12-month stock price target?

Biohaven Ltd. (BHVN) carries a 12-month consensus base price target of $15.6 (-5.4% from $16.49), with a bull-case target of $19.15 and a bear-case floor of $12.17.

Is BHVN stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates BHVN D (Sell — SELL) with an RQD Confidence score of 46/100.

Direct Sub-Reports: BHVN RQD Cockpit BHVN 12M Forecast BHVN Earnings & Move BHVN Dividends & DRIP BHVN Insiders & 13F BHVN Whale Options BHVN Profit Sankey BHVN News & Why